---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010313"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T13:25:52.405431+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics reports FY2022 revenue $6.7M, net loss $14.9M; cash $32M

## Summary
- Q4 2022 revenue $1.3M from licensed molecule sale to Wugen; full year $6.7M (nil in prior year).
- R&D expenses $9.3M for FY2022 (vs $8.2M), G&A $8.3M (vs $5.2M); net loss $14.9M (vs $12.9M).
- Cash, cash equivalents & short-term investments total $32.0M as of Dec 31, 2022; funding sufficient through next 12 months.
- Phase 1/1b trials for HCW9218 in solid tumors and advanced pancreatic cancer ongoing; Phase 1 completion targeted in 2023.
- CRADA with NCI for Phase 1b/2 pancreatic study; scientific paper on HCW9302 published in Frontiers in Immunology.

## SEC filing metadata
- accession: 0000950170-23-010313
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000095017023010313/0000950170-23-010313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000095017023010313/hcwb-20230328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010313
- JSON: https://secwatch.observer/filing/0000950170-23-010313.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010313.txt

## Key facts
- Earnings Releases
  HCW Biologics Inc. reported the year ended December 31, 2022 results: revenue $6.7 million.
  - Period: the year ended December 31, 2022
  - Revenue: $6.7 million
  - Result: reported results
  source text: Revenues for the year ended December 31, 2021 and 2022 were nil and $6.7 million, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828673/000095017023010313/0000950170-23-010313-index.htm
- Earnings Releases
  HCW Biologics Inc. reported the fourth quarter ended December 31, 2022 results: revenue $1.3 million.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $1.3 million
  - Result: reported results
  source text: Revenues for the fourth quarter ended December 31, 2021 and 2022 were nil and $1.3 million, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828673/000095017023010313/0000950170-23-010313-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.